Skip to main content

Table 2 Ceramides after Desipramine, Zoledronic Acid or Sphingolactone treatment

From: Ceramides: a potential therapeutic target in pulmonary emphysema

Sphingolipid

Control (n=5)

Control + Sph (n=9)

Control + ZA (n=9)

Control + Des (n=10)

Elastase (n=5)

Elastase + Sph (n=9)

Elastase + ZA (n=9)

Elastase + Des (n=10)

Ceramide 16:0

23.39 ± 2.92

25.55 ± 1.23

26.07 ± 2.85

32.70 ± 3.12 *

48.38 ± 4.46 *

53.07 ± 12.34 *$

44.47 ± 11.93 *$

63.15 ± 13.15 *#$

Ceramide 18:0

2.61 ± 0.54

2.74 ± 0.30

2.83 ± 0.20

4.01 ± 0.70

4.88 ± 0.60 *

5.66 ± 1.62 *$

4.43 ± 0.97 *$

7.45 ± 1.32 *#$

Ceramide 20:0

1.30 ± 0.34

1.24 ± 0.12

1.32 ± 0.14

1.97 ± 0.27

2.56 ± 0.37 *

2.86 ± 0.78 *$

2.44 ± 0.37 *$

4.07 ± 0.82 *#$

Ceramide 22:0

7.95 ± 2.41

7.37 ± 0.70

9.75 ± 1.29

14.17 ± 1.89 *

20.01 ± 4.39 *

20.43 ± 5.74 *$

19.80 ± 4.73 *$

33.90 ± 7.71 *#$

Ceramide 24:0

33.63 ± 13.22

25.92 ± 2.66

42.31 ± 6.19

56.01 ± 6.39 *

86.39 ± 22.72 *

71.40 ± 16.60 *$

84.40 ± 16.74 *$

145.10 ± 41.79 *#$

Ceramide 24:1

19.09 ± 6.27

17.97 ± 0.90

22.81 ± 4.10

33.25 ± 4.01 *

68.45 ± 19.42 *

64.66 ± 16.75 *$

70.20 ± 16.85 *$

113.70 ± 26.87 *#$

Dihydro Ceramide 18:0

0.32 ± 0.07

0.38 ± 0.23

0.39 ± 0.30

0.42 ± 0.08

0.88 ± 0.21 *

1.02 ± 0.35 *$

0.86 ± 0.20 *$

1.76 ± 0.24 *#$

Dihydro Ceramide 24:0

1.57 ± 0.67

1.67 ± 0.75

2.02 ± 1.11

2.32 ± 1.78

6.54 ± 1.78 *

6.28 ± 2.49 *$

6.29 ± 1.52 *$

13.11 ± 5.03 *#$

  1. BAL fluid was collected and processed using LCMS. Data are expressed as Mean + SEM in ng/ml BAL fluid. Des = Desimaprimine, ZA = Zoledronic Acid, Sph = Sphingolactone. *p<0.05 when compared to Control. # p<0.05 when compared to Elastase. $p<0.05 when compared to control group with the same inhibitor (Elastase + Sph vs. Control + Sph, Elastase + ZA vs. Control + ZA, Elastase + Des vs. Control + Des).